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Original Article
Quantification of [18F]florbetapir: A
test–retest tracer kinetic modelling study
Sandeep SV Golla1, Sander CJ Verfaillie1,2, Ronald Boellaard1,3,
Sofie M Adriaanse1, Marissa D Zwan2, Robert C Schuit1,
Tessa Timmers1,2, Colin Groot1, Patrick Schober4,
Philip Scheltens2, Wiesje M van der Flier2,5,
Albert D Windhorst1, Bart NM van Berckel1 and
Adriaan A Lammertsma1
Abstract
Accumulation of amyloid beta can be visualized using [18F]florbetapir positron emission tomography. The aim of this
study was to identify the optimal model for quantifying [18F]florbetapir uptake and to assess test–retest reliability of
corresponding outcome measures. Eight Alzheimer’s disease patients (age: 67 6 years, Mini-Mental State Examination
(MMSE): 23 3) and eight controls (age: 63 4 years, MMSE: 30 0) were included. Ninety-minute dynamic positron
emission tomography scans, together with arterial blood sampling, were acquired immediately following a bolus injection
of 294 32 MBq [18F]florbetapir. Several plasma input models and the simplified reference tissue model (SRTM) were
evaluated. The Akaike information criterion was used to identify the preferred kinetic model. Compared to controls,
Alzheimer’s disease patients had lower MMSE scores and evidence for cortical Ab pathology. A reversible two-tissue
compartment model with fitted blood volume fraction (2T4k_VB) was the preferred model for describing [
18F]florbetapir
kinetics. SRTM-derived non-displaceable binding potential (BPND) correlated well (r
2¼ 0.83, slope¼ 0.86) with plasma
input-derived distribution volume ratio. Test–retest reliability for plasma input-derived distribution volume ratio, SRTM-
derived BPND and SUVr(50–70) were r¼ 0.88, r¼ 0.91 and r¼ 0.86, respectively. In vivo kinetics of [18F]florbetapir could
best be described by a reversible two-tissue compartmental model and [18F]florbetapir BPND can be reliably estimated
using an SRTM.
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Introduction
Accumulation of amyloid beta (Ab) is one of the patho-
logical hallmarks of Alzheimer’s disease (AD),
which starts to accumulate years before clinical presen-
tation of dementia.1 Ab can be visualized using
[18F]florbetapir positron emission tomography (PET).
Accurate quantification of Ab is important for patient
management, monitoring progression of disease and
response to disease-modifying therapies.2–7
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Earlier studies with dynamic PET scans have shown
increased [18F]florbetapir uptake in the cortex, espe-
cially precuneus and fronto-temporal regions, of
patients with AD compared with healthy controls, pre-
sumably reflecting elevated accumulation of amyloid.8,9
To date, most studies have used the standardized
uptake value ratio (SUVr) as semi-quantitative measure
of [18F]florbetapir uptake. Test–retest studies, however,
have generated inconsistent findings with regard to
SUVr optimisation.10–13 SUVr may be too biased to
identify near normal levels of amyloid deposition.
More importantly, tracer kinetics and distribution are
likely to be affected by underlying pathophysiological
mechanisms, such as decreased perfusion known
to occur in AD16. Effects of perfusion changes on
bias in SUVr have already been documented for
[11C]PiB.14
A validated tracer kinetic model is important, not
only for identification of early (subtle) amyloid accu-
mulation, but also for longitudinal assessment of
changes in amyloid depositions.14 This is also the case
for [18F]florbetapir, a widely used amyloid tracer, espe-
cially when it is used as a surrogate marker for assessing
the efficacy of disease modifying drugs.7 Therefore, the
main objective of this study was to identify the optimal
tracer kinetic model for quantification of
[18F]florbetapir binding, taking into account both
test–retest reliability and optimisation of scan duration.
Material and methods
Participants
Eight patients with probable AD3 from the Amsterdam
Dementia Cohort17 were included. Screening included
physical and neurological examinations, medical his-
tory, extensive neuropsychological assessment, brain
MRI, lumbar puncture and laboratory measurements
(e.g. haemoglobin levels). AD patients were eligible
when Mini-Mental State Examination (MMSE) scores
were 19. Eight healthy control subjects were recruited
through advertisements in newspapers. These controls
were in good physical health, experienced no cognitive
complaints and met Research Diagnostic Criteria for
‘‘never mentally ill.’’18 Controls underwent a similar
screening (except for lumbar puncture) as AD patients
and were only eligible if results of all clinical assess-
ments were within corresponding normal ranges. The
study was approved by the local Medical Ethics Review
Committee of the VU University Medical Center, and
all subjects provided written informed consent, in line
with the Helsinki Declaration of 1975 (and 1983
revised) guidelines.
[18F]florbetapir synthesis
Individual doses of [18F]florbetapir were prepared on
site in accordance with Avid Radiopharmaceuticals
Investigational quality control release criteria.
Data acquisition
Data were acquired using an Ingenuity TF PET/CT
scanner (Philips Medical Systems, Best, the
Netherlands). Prior to scanning, two cannulas were
inserted, one for intravenous [18F]florbetapir adminis-
tration and the other for arterial sampling. First, a low-
dose computed tomography (CT) scan was performed
for attenuation correction purposes. Each subject
underwent two [18F]florbetapir PET scans (average
interval: 4 2 weeks). Following the low-dose CT, a
90-min PET emission scan was acquired after a bolus
injection of 370 MBq (initial six scans) or 425 MBq
(subsequent 26 scans) [18F]florbetapir. This increase in
injected dose after six scans (three subjects) was intro-
duced because of significant sticking of [18F]florbetapir
to the wall of the injection catheter. Arterial blood was
sampled continuously at a rate of 5mLmin1 for the
first 5min and 2.5mLmin1 thereafter, using an online
detection system.19 At set times (5, 10, 20, 40, 60, 75
and 90min), continuous withdrawal was interrupted
briefly for the collection of manual blood samples
(8mL each), which were used to estimate plasma-
to-whole-blood ratios and to measure plasma metabol-
ite fractions.
For brain tissue segmentation and PET co-registra-
tion, structural MRI scans (3D T1-weighted using a
magnetization-prepared rapid gradient-echo sequence)
were acquired at 3.0 Tesla using either a Signa HDxt
MRI (General Electric, Milwaukee, WI) or an
Ingenuity TF PET/MR (Philips Medical Systems,
Cleveland, OH) scanner.
Radiometabolite analysis
Blood was collected in heparin tubes and centrifuged
for 5min at 5000 r/min. Plasma was separated from
blood cells, and about 1mL was diluted with 2mL
water and loaded onto a tC18 Sep-Pak cartridge
(Waters, Milford, MA), which was pre-activated by elu-
tion with 6mL of methanol and 12mL of water,
respectively. The cartridge was washed with 3mL
water to collect the polar radioactive fraction.
Thereafter, the tC18 Sep-Pak cartridge was eluted
with 2mL of methanol and 2mL of water to collect
the mixture of non-polar metabolites. This fraction
was further analysed by HPLC using an Ultimate
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3000 system (Dionex, Sunnyvale, CA) equipped with a
1-mL loop. As a stationary phase, a Gemini C18,
250 10mm, 5 mm (Phenomenex, Torrance, CA)
was used. The mobile phase was a gradient of
A¼ acetonitrile and B¼ 0.1% trifluoroacetic acid in
water. The gradient ran for 15min, decreasing the con-
centration of eluent B from 90% to 40% in 11min,
followed by 1min of elution with 40% B at a flow
rate of 4mLmin1. The eluent was collected with a
fraction collector (Teledyne ISCO Foxy Jr., Lincoln,
NE), and the fractions were counted for radioactivity
using a Wallac 2470 gamma counter (Perkin Elmer,
Waltham, MA).
Data analysis
PET images of 22 frames (1 15, 3 5, 3 10, 4 60,
2 150, 2 300 and 7 600 s) with a matrix size of
128 128 90 voxels and a final voxel size of
2 2 2 mm3 were reconstructed using 3D row
action maximum likelihood algorithm. During recon-
struction, all usual corrections for attenuation, scatter,
randoms, decay and dead time were performed.
Structural 3D T1-weighted MRI images were co-regis-
tered to the PET images. Using PVElab20 together with
the Hammers template,21 regions of interest (ROIs)
were delineated on the MRI scan and superimposed
onto the dynamic PET scan to obtain regional time
activity curves (TACs).
Using the information extracted from manual blood
samples, online arterial blood TACs were calibrated
and corrected for plasma to whole blood ratios, radi-
olabelled metabolites and delay, thereby generating
individual metabolite corrected plasma input functions.
Due to difficulties with blood data metabolite analysis
(e.g. HPLC peak isolation, after four scan methods for
peak separation were optimized, blood metabolite
failed finally during n¼ 5 scans), missing values
during online (continuous) detection of blood data
within the first 5min (n¼ 3 participants), and insuffi-
cient blood sample volumes (1 scan), plasma input-
based pharmacokinetic test–retest analyses (using the
original metabolite information) were performed for
only five AD patients and four controls. There were
six controls and eight AD patients from which we
had blood data available from at least one satisfactory
scan session and blood data. Because of the high intra-
subject variability in parent fraction estimates, input
functions were also derived using (1) a population aver-
age parent fraction (i.e. mean of all reliable parent frac-
tions from all data sets) and (2) an intra-subject average
parent fraction (i.e. mean parent fraction of test and
retest scans). Parent fraction estimations are presented
separately for controls and AD patients in
Supplementary Figure 1, whilst Supplementary Figure
2 shows all three input functions for a representative
control subject and an AD patient.
Several tracer kinetic models22 were used to fit the
regional TACs, i.e. single tissue reversible (1T2k), and
two tissue irreversible (2T3k) and reversible (2T4k)
compartmental models, all with and without (VB)
blood volume as additional fit parameter. The Akaike
information criterion (AIC)23 was used to identify the
optimal pharmacokinetic model for in vivo kinetics of
[18F]florbetapir. In addition, the simplified reference
tissue model (SRTM)24 and SUVr were assessed by
comparing SRTM-derived non-displaceable binding
potential (BPND) and SUVr with distribution volume
ratio (DVR). Cerebellar grey matter was used as refer-
ence region.
Test–retest (TRT) reliability of both micropara-
meters (in particular the rate constant from blood to
tissue K1) and macroparameters (distribution volume
VT, DVR, BPND and SUVr(50–70)) was estimated for
the preferred model and selected simplified methods.
In addition, the impact of scan duration on model pref-
erences, parameter values and TRT reliability was
assessed. Finally, a separate comparison was made of
parameter values for both controls and AD patients.
This comparison was performed as an exploratory
evaluation of the effects of the disease on tracer
kinetics.
Statistical analyses
Statistical analyses were performed using SPSS version
20.0.0 (IBM Corp., Armonk, NY). To investigate
demographic, clinical and neuroimaging (i.e. SRTM-
derived BPND group comparisons) data, 
2 tests for
discrete variables and t tests for continuous data were
used. Assumptions for normal distribution were
checked using Kolmorogov–Smirnov tests. AIC was
used to compare the model fits for regional TACs in
order to identify the optimal tracer kinetic model.
Standard deviations were used to evaluate the reliabil-
ity of estimated parameters. TRT reliability was
expressed as the Pearson correlation coefficient (r) of
the parameter of interest between test and retest data,
which was calculated for plasma input (K1, VT and
DVR) and SRTM (R1 and BPND)-derived parameters.
Results
Demographic and clinical data are presented in Table 1.
Net injected dose and specific activity were comparable
between groups, and between test and retest scans
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(all p values> 0.05). There were no differences in age,
sex, body weight and length between patients with AD
and controls (all p values> 0.05). MMSE scores were
lower in AD patients than in controls (p< 0.001).
Visual assessment of the [18F]florbetapir PET scans
showed that all healthy controls showed no evidence
of abnormal amyloid accumulation, whereas all
patients with AD showed abnormal amyloid
accumulation.
All plasma input-based kinetic analyses were per-
formed on data of four controls and five AD patients.
Tracer metabolism in plasma was relatively fast with
parent fractions of about 60% and 20% after 5 - and
90-min post-injection (Figure 1), respectively.
According to AIC, the 2T4k_VB model described
in vivo [18F]florbetapir kinetics best, irrespective of sub-
ject, ROI and type of input function. BPND (¼k3/k4)
values obtained using 2T4k_VB did not correlate well
with DVR-1, the indirect plasma input binding estimate
(r2¼ 0.01, slope¼ 0.06). This most likely is due to poor
precision (high standard deviations) of direct BPND esti-
mates. For reference region-based analyses, data of eight
controls and eight patients were used. There was a strong
correlation between SRTM-derived BPND and plasma
input DVR values (r2¼ 0.83, slope¼ 0.86 across all sub-
jects, r2¼ 0.93 for AD, r2¼ 0.73 for controls; Figure 2).
Across subjects, different SUVr time intervals pro-
vided results that were comparable with DVR (original
input function) for all ROIs. Figure 3 shows SUVr
plots of whole brain grey matter together with a com-
parison of SUVr values obtained using different scan
intervals with DVR (original input function) for all
ROIs of all subjects. Irrespective of time intervals,
SUVr overestimated (i.e. slope> 1) [18F]florbetapir
binding when compared with DVR. Comparable cor-
relation coefficients (r2¼ 0.86) and slopes (1.11)
were observed for different SUVr time intervals
(>40min) for all subjects (Figure 3(b)), with
Table 1. Clinical and demographic data.
Controls (n¼ 8) AD patients (n¼ 8) p value
Age 63.0 (4.4) 66.8 (5.9) p¼ 0.17
Males/females (n) 3/5 3/5 NA
MMSE 29.8 (0.5) 22.6 (3.3) p< 0.001
Body weight (in kg) 84.9 (14.6) 84.6 (12.3) p¼ 0.97
Body length (in cm) 178.0 (12.9) 178.4 (8.7) p¼ 0.95
Test Retest Test Retest
Injected dose (MBq) 288 (42) 283 (36) 287 (39) 316 (10) pw¼ 0.24, pb¼ 0.17
Specific activity (mg/mL) 3 (1) 4 (1) 3 (1) 4 (1) pw¼ 0.37, pb¼ 0.87
Note: Data are presented as mean (SD).
BPND: non-displaceable binding potential; p
w: p value between test and retest measurements; pb: p value between AD and controls; SD: standard
deviation; AD: Alzheimer’s disease; MMSE: Mini-Mental State Examination (range: 0–30); NA: not applicable.
Figure 2. Comparison of SRTM-derived BPND against plasma
input (Original IP)-derived DVR. Original IP is the input function
obtained using original parent fractions.
AD: Alzheimer’s disease; C: controls; DVR: distribution volume
ratio; SRTM: simplified reference tissue model; BPND: non-dis-
placeable binding potential; IP: input; LOI: line of identity.
Figure 1. Parent [18F]florbetapir and polar metabolite fractions
(mean SD) in arterial plasma at different time points.
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substantially lower correlation coefficients for controls
(e.g. SUVr(50–70) r
2¼ 0.61, slope¼ 0.88) compared to
AD (e.g. SUVr(50–70) r
2¼ 0.88, slope¼ 1.11).
A TRT reliability coefficient (r) of 0.75 was found for
individual plasma input function-derived VT values, with
improved TRT reliability coefficients of 0.87 and 0.86 for
VT values obtained using population averaged and intra-
subject averaged metabolite corrected plasma input func-
tions, respectively. DVR, SRTM-derived BPND and
SUVr(50–70) showed TRT reliability coefficients of 0.88,
0.91 and 0.86, respectively. Figure 4 illustrates TRT reli-
ability of VT and DVR values across all volumes of inter-
est for the three different types of input functions.
Finally, Figure 5 shows the impact of overall scan
duration on estimated values of VT, DVR and SRTM-
derived BPND. TRT reliability of the kinetic parameters
obtained for different scan durations is provided in
Table 2. When comparing AD patients with healthy
controls, increased cortical SRTM BPND was found
in temporal lobe (controls (mean SD) 0.02 0.04,
AD 0.31 0.04, p< 0.001), frontal lobe (controls
0.08 0.05, AD 0.43 0.06, p< 0.001), occipital lobe
(controls 0.19 0.03, AD 0.34 0.14, p¼ 0.07), par-
ietal lobe (controls 0.02 0.03, AD 0.23 0.03,
p< 0.001), posterior cingulate cortex (controls
0.23 0.17, AD 0.55 0.04, p¼ 0.004), but not in the
hippocampus (controls 0.02 0.05, AD 0.07 0.05,
p¼ 0.16).
Discussion
This study demonstrated that in vivo kinetics of
[18F]florbetapir could best be described by a reversible
two tissue compartmental model with blood volume
parameter (i.e. 2T4k_VB). This model produced
robust and consistent longitudinal results for all input
functions, which did not vary between brain regions.
Furthermore, of the reference tissue-based parameter
estimates, SRTM-derived BPND showed least
bias, whereas SUVr consistently overestimated
[18F]florbetapir uptake. In addition, TRT reliability
was poorer for SUVr than for BPND.
The present findings with regard to the model prefer-
ence are in line with another recent study,25 and add-
itionally showed that model preference was independent
of type of input function and scan duration. Kinetics of
[18F]florbetapir appeared to be rather rapid in vivo, and
model preference did not change when data were
restricted to 40min. Compared with 90-min scan dur-
ation, TRT reliability of kinetic parameters started to
deviate for shorter scan durations. Interestingly,
SRTM-derived BPND, plasma input-derived DVR-1
and VT correlated well with the corresponding 90-min
parameter estimates, even for a scan duration of 50min.
Although, based on this comparison, scan duration
could be shortened to 50min, TRT values indicated
that a scan duration of 60min would be required to
obtain reproducible SRTM-derived BPND and R1
values without substantial bias compared with corres-
ponding 90-min estimates. Although plasma input-
derived VT and DVR for 50- and 60-min data were com-
parable with corresponding 90-min estimates, the overall
reproducibility was poorer than for reference tissue-
based parameter estimates.
Unfortunately, isolation of HPLC peaks was unsat-
isfactory during the first four studies, and VT obtained
from the 2T4k_VB model was affected by inaccuracies
in parent fraction estimations. Initially, the temporal
resolution of offline radioactivity detection (30-s frac-
tions) was not sufficient to separate metabolite peaks on
HPLC. To circumvent this problem, more fractions
were collected around the two peaks that were present.
Figure 3. (a) Average whole brain grey matter SUVr values as
function of time for each subject. Different symbols represent
subjects (red lines are AD patients and blue lines are controls).
(b) Comparison of SUVr obtained from data of different scan
durations (40–50min, 50–60min and 50–70min) against DVR,
for all regions of interest included in the Hammers template.
AD: Alzheimer’s disease; C: controls; DVR: distribution volume
ratio; SUVr: standardized uptake value ratio.
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Figure 5. Impact of scan duration on kinetic parameter estimates: VT (a, b and c), DVR (d, e and f), SRTM BPND (g, h and i). Reliability
of estimated parameters decreased for shorter scan durations, similarly between test (red points) and retest (blue points) data.
DVR: distribution volume ratio; LOI: line of identity.
Figure 4. %TRT reliability of (a) VT and (b) DVR observed in all Hammers template defined brain regions of both AD patients and
controls, when using either of the three input functions. Original IP is the input function obtained using original parent fractions; POP
IP is the input function obtained using population average parent fractions; Intra-pat IP is the input function obtained using intra subject
average (test–retest) parent fractions.
TRT: test–retest; DVR: distribution volume ratio.
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Although this improved accuracy, at the same time
count rates for each fraction were lower, reducing pre-
cision and, consequently, less reproducible parent frac-
tion estimates. Unreliable parent fractions will, in turn,
result in unreliable kinetic parameter estimates. For this
reason, intra-subject averaged and population averaged
parent fractions were investigated, and they resulted in
better TRT of VT values compared with those obtained
with individually measured parent fractions. A TRT of
less than 5% was observed for DVR and SRTM-
derived BPND, indicating that the probable reason for
the relatively high TRT of VT was indeed due to the
error in parent fraction estimates. Interestingly, even
when using population/intra-subject averaged parent
fractions, the TRT of VT was as high as 20%. One of
the reasons for this might be that the use of a popula-
tion average does not account for genuine inter-subject
differences in tracer metabolism.
A point of concern is whether non-polar metabolites
enter the brain and affect tissue kinetics. Non-polar
metabolites were not characterized in this study and
hence their nature is not known. However, in case of
influx of non-polar metabolites in the brain, a slow
and gradual increase in the uptake would be anticipated.
This should lead to an irreversible nature in the regional
TACs particularly for regions devoid of amyloid load,
which was not observed for any ROI in this subject
group. On the other hand, tissue TACs were well
described by the 2T4k_VB model, irrespective of the sub-
ject status, region size or the underlying amyloid load.
Although, this is not absolute proof that non-polar
metabolites do not enter the brain, it suggests that sub-
stantial influx of non-polar metabolites does not occur,
at least not within the time frame of the scan.
SRTM BPND values corresponded well with plasma
input DVR values, with the strongest correspondence
found for AD patients. This could be explained by the
observation that all AD patients in this study showed
evidence of abnormal amyloid accumulation.
Notwithstanding, for controls, there was also a good
correspondence between plasma input DVR and
SRTM BPND, which suggests that SRTM can provide
reproducible findings even in cases with lower or lim-
ited amounts of cortical Ab. As expected, increased
SRTM BPND values were found in AD patients com-
pared with controls in all cortical lobar regions except
the occipital lobe.9 Reproducible TRT values were
found for SRTM with a minimum of 60-min scan dur-
ation. Therefore, SRTM should be the method of
choice provided the reference tissue is not affected by
amyloid disposition. Future studies should investigate
which parametric method can be used for visual inter-
pretation of [18F]florbetapir.
Despite a consistent overestimation, SUVr corre-
lated well with plasma input-derived DVR. In a
recent study,25 SUVr was validated against VT. This
comparison, however, suffered from the fact that both
VT and SUVr depend on signals from free, specifically
bound and non-specifically bound tracer. To assess
whether SUVr is a good measure of amyloid load, it
is necessary to validate it against BPND, which only
represents specific binding. The most commonly used
SUVr time interval for [18F]florbetapir is 50- to 70-min
post-injection.8,9 In this study, SUVr became constant
from about 40min onwards and, accordingly, a con-
stant overestimation of approximately 10% compared
with DVR was observed, independent of actual scan
duration (>40min), with substantially poorer perform-
ance in controls compared to AD. This suggests that, at
least for the subjects included in this study, SUVr using
a 40 - to 50-min scan interval could be sufficient
as a semi-quantitative measure of amyloid load.
Nevertheless, further studies in larger patient cohorts
are needed to assess whether the bias in SUVr is indeed
Table 2. Kinetic parameters for different scan durations.
90 min 60 min 50 min 40 min
AD C AD C AD C AD C
TRT Slope TRT Slope TRT Slope TRT Slope TRT Slope TRT Slope TRT Slope TRT Slope
DVRa 0.84 0.85 0.78 0.75 0.69 0.70 0.70 0.61 0.58 0.55 0.61 0.50 0.51 0.45 0.40 0.32
SRTM BPND 0.87 0.90 0.91 0.87 0.83 0.91 0.90 0.89 0.74 0.87 0.82 0.76 0.76 0.80 0.79 0.71
SRTM R1 0.94 1.00 0.95 0.96 0.95 1.00 0.95 0.96 0.94 1.00 0.95 0.96 0.95 0.99 0.96 0.96
VT
a 0.78 1.10 0.09 0.11 0.69 0.90 0.21 0.20 0.58 0.70 0.38 0.31 0.49 0.59 0.36 0.29
K1
a 0.77 1.03 0.62 0.65 0.77 1.03 0.61 0.64 0.77 1.02 0.60 0.62 0.76 1.04 0.59 0.62
Note: TRT (r2) and slopes (60, 50 or 40min) are based on comparisons with 90-min PET scans. Ninety-minute comparisons were done against
2T4k_VB values.
TRT: test–retest; PET: positron emission tomography; AD: Alzheimer’s disease; C: controls; DVR: distribution volume ratio; SRTM: simplified reference
tissue model; BPND: non-displaceable binding potential.
aObtained using 2T4k_VB and input function processed using the individual measured parent fractions.
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constant. In addition, simulation studies are required to
assess whether the bias in SUVr varies with physiolo-
gically relevant changes in perfusion.
One limitation of a reference region approach is the
potential presence of amyloid in the reference region, in
this case grey matter cerebellum, as this would result in
underestimation of the specific signal from other
regions. The only way to confirm that a reference
region is completely devoid of specific binding is by
performing a pharmacological blocking study, but for
amyloid tracers, this is not possible in humans.
Considering that essentially no specific binding is present
in grey matter cerebellum of controls, an alternative is to
evaluate whether there is any difference in grey matter
cerebellum VT between AD patients and controls. Such a
difference was not seen, indicating that grey matter cere-
bellum can be used as a reference region. Nevertheless,
further studies are needed to validate the use of grey
matter cerebellum as reference region.
Conclusions
The 2T4k_VB model is the preferred plasma input
model for describing in vivo kinetics of
[18F]florbetapir in both healthy controls and AD
patients. Unfortunately, VT seems to be affected by
uncertainties in parent fraction estimates. Therefore,
when a reliable reference region exists, SRTM is the
preferred method of analysis, as it is both the most
reliable and the most reproducible method, and scan
duration can be reduced to 60min.
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